Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Sane, S ^a   Abdullah, A ^a   Boudreau, D A ^a   Autenried, R K ^a   Gupta, B K ^c   Wang, X ^b   Wang, H ^a   Schlenker, E H ^a   Zhang, D ^a   Telleria, C ^a   Huang, L ^b   Chauhan, S C ^c   Rezvani, K ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Colorectal cancer; Mot 2; P53; UBXN2A; Xenograft

Indexed keywords

HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 MORTALIN 2; PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; UBIQUITIN LIKE DOMAIN CONTAINING PROTEIN 2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CELL STRAIN HCT116; CELL STRAIN HEK293; CELL STRAIN MCF 7; CHEMICAL ANALYSIS; COLON CANCER; CONTROLLED STUDY; CYTOSOLIC FRACTION; DRUG PROTEIN BINDING; EMBRYO; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENETIC ANALYSIS; HELA CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; BINDING SITES; BINDING, COMPETITIVE; CASPASE 3; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HCT116 CELLS; HEK293 CELLS; HSP70 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MITOCHONDRIAL PROTEINS; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897430074     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.100     Document Type: Article

References (59)

1. Luo WI, Dizin E, Yoon T, Cowan JA. Kinetic and structural characterization of human mortalin. Protein Expr Purif 2010; 72: 75-81.
2. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005; 205: 74-81.
3. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, Mitsui Y. Elevated levels of mortalin expression in human brain tumors. Exp Cell Res 1997; 237: 38-45.
4. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006; 118: 2973-2980.
5. Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci USA 1996; 93: 15190-15194.
6. Gestl EE, Anne Bottger S. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochem Biophys Res Commun 2012; 423: 411-416.
7. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R et al. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 2011; 6: 1046-1056.
8. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998; 273: 29586-29591.
9. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R et al. Induction of mutant p53- dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 2011; 129: 1806-1814.
10. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21: 271-276.
11. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8: 25-37.
12. Alexandru G, Graumann J, Smith GT, Kolawa NJ, Fang R, Deshaies RJ. UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover. Cell 2008; 134: 804-816.
13. Haines DS. p97-containing complexes in proliferation control and cancer: emerging culprits or guilt by association? Genes Cancer 2010; 1: 753-763.
14. Lee JJ, Kim YM, Jeong J, Bae DS, Lee KJ. Ubiquitin-associated (UBA) domain in human Fas associated factor 1 inhibits tumor formation by promoting Hsp70 degradation. PLoS One 2012; 7: e40361.
15. Rezvani K, Teng Y, Pan Y, Dani JA, Lindstrom J, Garcia Gras EA et al. UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3- containing nicotinic acetylcholine receptors. J Neurosci 2009; 29: 6883-6896.
16. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.
17. Fang L, Kaake RM, Patel VR, Yang Y, Baldi P, Huang L. Mapping the protein interaction network of the human COP9 signalosome complex using a label-free QTAX strategy. Mol Cell Proteomics 2012; 11: 138-147.
18. Rezvani K, Baalman K, Teng Y, Mee MP, Dawson SP, Wang H et al. Proteasomal degradation of the metabotropic glutamate receptor 1alpha is mediated by Homer-3 via the proteasomal S8 ATPase: Signal transduction and synaptic transmission. J Neurochem 2012; 122: 24-37.
19. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 2002; 274: 246-253.
20. Grover A, Priyandoko D, Gao R, Shandilya A, Widodo N, Bisaria VS et al. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence. Int J Biochem Cell Biol 2012; 44: 496-504.
21. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 2005; 280: 39373-39379.
22. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R et al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000; 60: 6818-6821.
23. Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD et al. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 2007; 67: 709-717.
24. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345-357.
25. Yang SY, Sales KM, Fuller BJ, Seifalian AM, Winslet MC. Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide. Mol Cancer 2008; 7: 17.
26. Ishii T, Fujishiro M, Masuda M, Okudela K, Kitamura H, Teramoto S et al. Nutritional deficiency affects cell cycle status and viability in A549 cells: role of p27Kip1. Cancer Lett 2004; 213: 99-109.
27. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29(Pt 6): 684-688.
28. Kim WH, Yeo M, Kim MS, Chun SB, Shin EC, Park JH et al. Role of caspase-3 in apoptosis of colon cancer cells induced by nonsteroidal anti-inflammatory drugs. Int J Colorectal Dis 2000; 15: 105-111.
29. Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, Schiesling C et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet 2010; 19: 4437-4452.
30. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013; 23: 93-106.
31. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, WangWet al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 2011; 108: 14240-14245.
32. Iosefson O, Azem A. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins-identification of additional interacting regions. FEBS Lett 2010; 584: 1080-1084.
33. Utomo DH, Widodo N, Rifa'i M. Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening. Bioinformation 2012; 8: 426-429.
34. Kaul SC, Reddel RR, Mitsui Y, Wadhwa R. An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia 2001; 3: 110-114.
35. Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H et al. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer 2013; 3, Print ISSN 1436-3291.
36. Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 2006; 6: 1049-1049.
37. Lopergolo A, Pennati M, Gandellini P, Orlotti NI, Poma P, Daidone MG et al. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Br J Cancer 2009; 100: 739-746.
38. Pines A, Kelstrup CD, Vrouwe MG, Puigvert JC, Typas D, Misovic B et al. Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells. Mol Cell Biol 2011; 31: 4964-4977.
39. Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 2013; 32: 388-396.
40. Vakifahmetoglu H, Olsson M, Orrenius S, Zhivotovsky B. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 2006; 25: 5683-5692.
41. Noble P, Vyas M, Al-Attar A, Durrant S, Scholefield J, Durrant L. High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer 2013; 108: 2097-2105.
42. Kaul SC, Duncan EL, Englezou A, Takano S, Reddel RR, Mitsui Y et al. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene 1998; 17: 907-911.
43. Kaula SC, Reddelb RR, Sugiharac T, Mitsuia Y, Wadhwac R. Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. FEBS Lett 2000; 474: 159-164.
44. Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z et al. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem J 2005; 391(Pt 2): 185-190.
45. Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/ Grp75: what, when, and where? Cell Stress Chaperones 2002; 7: 309-316.
46. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
47. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, Gimenez- Bonafe P et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 2011; 6: e18588.
48. Wang S, Zhao Y, Bernard D, Aguilar A, Kumar S. Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. In: Wendt MD (ed) Protein-Protein Interactions. Springer: Berlin Heidelberg, 2012; vol. 8, pp 57-79.
49. Chan AL, Grossman T, Zuckerman V, Campigli Di Giammartino D, Moshel O, Scheffner M et al. c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase activity. Biochemistry 2013; 52: 3119-3129.
50. Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine JC et al. c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem 2009; 284: 4031-4039.
51. Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH et al. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res 2011; 71: 884-894.
52. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
53. Zhang Y, Wang J, Yuan Y, Zhang W, Guan W, Wu Z et al. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res 2010; 38: 6544-6554.
54. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS et al. Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci USA 2004; 101: 3456-3461.
55. Halaby MJ, Hakem A, Li L, El Ghamrasni S, Venkatesan S, Hande PM et al. Synergistic interaction of Rnf8 and p53 in the protection against genomic instability and tumorigenesis. PLoS Genet 2013; 9: e1003259.
56. Toiyama Y, Inoue Y, Yasuda H, Saigusa S, Yokoe T, Okugawa Y et al. DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness. J Gastroenterol 2011; 46: 153-163.
57. Kudo T, Ikeda M, Nishikawa M, Yang Z, Ohno K, Nakagawa K et al. The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. Cancer Res 2012; 72: 2901-2911.
58. Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC et al. Sp1 expression regulates lung tumor progression. Oncogene 2012; 31: 3973-3988.
59. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007; 13: 3370-3379.